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Abstracts 
 
CBFA2T3-GLIS2 is a fusion gene identified in 7-8% of pediatric acute myeloid leukemia with poor 
outcome. This fusion gene drives a peculiar expression pattern and leads to overexpression of some 
of Hedgehog related genes. GLI similar protein 2 (GLIS2) is closely related to the GLI family, the 
final effectors of classic Hedgehog pathway. These observations lend compelling weight to the 
application of GLI inhibitors in the treatment of AML with the aberration CBFA2T3-GLIS2. 
GANT61 is an inhibitor of GLI proteins. The exposure to the GANT61 resulted in higher sensitivity 
of cell lines and primary AML cells carrying CBFA2T3-GLIS2 than the AML cells without GLIS2 
fusion as well as in promoting apoptosis and downregulation of GLIS2 specific signature genes. 
Moreover, ChIP analysis revealed direct regulation by GLIS2 chimeric protein of DNMT1 and 
DNMT3B, two genes implicated in important epigenetic functions. Furthermore, considering the 
limitations of cell lines model we set up a model based on induced pluripotent stem cells (iPSC) 
derived from healthy donor engineered to express CBFA2T3-GLIS2 fusion gene. We demonstrated 
that CBFA2T3-GLIS2 and other targets of fusion gene were expressed in hematopoietic cells 
derived from iPSC differentiation. The CD43+ hematopoietic cells were composed of a higher 
percentage of CD41+CD42+ megakaryocytic cells. Importantly, we observed strong differentiation 
alterations, including a lower expression of CD61 on CBFA2T3-GLIS2 megakaryocytes compared 
to controls and a progressive accumulation of an abnormal CD41
low
CD42
low
 population never 
detected in control conditions. Finally, clonogenic assays in methylcellulose indicated that 
CBFA2T3-GLIS2 enhances serial replating activity for several weeks. Moreover treatment with 
GANT61 affected proliferation of CBFA2T3-GLIS2 hematopoietic cells derived from iPSC 
differentiation.  
Taken together, our findings indicate that the GLI inhibitor GANT61 may be used to specifically 
target the CBFA2T3-GLIS2 fusion in pediatric AML.  
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1. Introduction 
 
1.1 Pediatric Acute Myeloid Leukemia 
 
Acute myeloid leukemia (AML) is a group of genetically heterogeneous hematopoietic disorders of 
the myeloid lineage characterized by the uncontrolled growth and clonal expansion without 
complete differentiation of a hematopoietic/stem progenitor 
1
. 
Acute myeloid leukemia represents the 15-20% of the entire Acute leukemia in children. The 
incidence of AML in infants is 1.5 per 100,000 individuals per year, the incidence decreases to 0.9 
per 100,000 individuals aged 1–4 and 0.4 per 100,000 individuals aged 5–9 years, after which it 
gradually increases into adulthood
1
. The underlying cause of AML is unknown, and childhood 
AML generally occurs de novo. In adult and elderly patients, AML is often preceded by 
myelodysplastic syndrome (MDS), but in children, the occurrence of AML preceded by clonal 
evolution of preleukemic myeloproliferative diseases, such as myelodysplastic syndrome (MDS) or 
juvenile myelomonocytic leukemia (JMML), is rare. Germline affected individuals, such as those 
with Fanconi anemia or Bloom syndrome, have an increased risk for developing AML as a 
secondary malignancy 
2, 3
. Recently, germ-line mutations in several genes, such as TP53, RUNX1, 
GATA2 and CEBPA, have been found in families with an unexplained high risk of AML, 
suggesting a familial predisposition to develop AML 
4-9
. Children with Down syndrome classically 
present with a unique megakaryoblastic subtype of AML, classically following a transient 
myeloproliferative disorder in the neonatal period, which is characterized by somatic mutations in 
the GATA1 gene. In addition, AML may occur following previous radiotherapy or chemotherapy 
containing alkylating agents or epipodophyllotoxins, as secondary neoplasm. These are typically 
characterized by either MLL-rearrangements or by monosomy 7 
9, 10
. 
 
1.3 Classification and overall outcome 
 
Prognosis of childhood acute myeloid leukemia (AML) has improved significantly over the past 
decades, the current probability of cure being approximately 60% in most of the developed 
countries 
11
. This result has been achieved thanks to not only the use of more effective anti-
leukemic agents and significant improvements in supportive care, but also to the progress made in 
the stratification of patients with a consequent risk-directed therapy 
12-14
. 
8 
 
The first classification of AML was  provided by the French-American-British (FAB) classification. 
The FAB classification was based on the morphological and histological characteristics of the 
leukemic cells  as well as stage of differentiation of the leukemic blasts 
15
 (Table 1) . 
 
Table 1. French-America-British (FAB) classification for AML 
 
M0 AML with no Romanowsky or cytochemical evidence of differentiation 
M1 Myeloblastic leukemia with litter maturation 
M2 Myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia 
M3h Acute promyelocytic leukemia, hypergranular variant 
M3v Acute promyelocytic leukemia, microgranular variant 
M4 Actue myelomonocytic leukemia 
M4eo Actue myelomonocytic leukemia with dysplastic marrow meosinophils 
M5 Acute monoblastic leukemia 
M5a Acute monoblastic leukemia, poorly differentiated 
M5b Acute monoblastic leukemia, differentiated 
M6 Erytroleukemia 
M7 Acute megakaryoblastic leukemia 
 
Modified from Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the 
classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 
Aug;33(4):451-8. 
 
 
Although the FAB classification remains useful and commonly used is nowadays replaced by the 
World Health Organization (WHO) classification, which also takes karyotype and molecular 
aberrations into account (Table 2) 
16
. 
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Table 2. The World Health Organization (WHO) classification of acute myeloid leukemia 
Acute myeloid leukemia with recurrent genetic abnormalities 
AML with balanced translocations/inversions 
Acute myeloid leukemia with t(8;21)(q22;q22); AML/ETO 
Acute myeloid leukemia with inv(16)(p13;q22) or t(16;16)(p13;q22); CBFB/MYH11 
Acute myeloid leukemia with t(15;17)(q22;q21); PML/RARα 
Acute myeloid leukemia with t(9;11)(p22;q23); MLL/AF9 
Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); OTT/MAL 
Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)( q21;q26.2); RPN1/EVL1 
Acute myeloid leukemia with t(6;9)(p23;q34); DEK/NUP124 
AML with gene mutations 
Mutation affecting FLT3, NPM1, C/EBPα, KIT, MLL, WT1, NRAS and KRAS 
Acute myeloid leukemia with myelodisplasia-related changes 
Acute leukemia with 20% or more peripheral blood or bone marrow blasts with morphological features of 
myelodysplasia or a prior history of a myelodyplastic syndrome (MDS) or 
myelodyplastyic/myeloproliferative neoplasm (MDS/MPN), or MDS-related cytogenetic abnormalities, and 
absence of the specific genetic abnormalities of AML. 
Therapy-related myeloid neoplasms 
Therapy-related acute myeloid leukemia (tAML), myelodysplastic syndrome (tMDS), and 
myelodyplastyic/myeloproliferative neoplasm (tMDS/MPN) occurring as late complications of cytotoxic 
chemotherapy and/or radiation therapy administered for a prior neoplastic or non-neoplastic disorder. 
Acute myeloid leukemia, not otherwise specified 
FAB classification (M0, M1, M2, M3, M3h, M3v, M4, M4eo, M5, M5a, M5b, M6, M7. 
Myeloid sarcoma 
Tumor mass consisting of myeloid blasts with/without maturation, occurring at an anatomical site other than 
the bone marrow. 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Clinically aggressive tumor derived from the precursors of plasmacytoid dendritic cells, with a high 
frequency of cutaneous and bone marrow involvement and leukemic dissemination. 
Modified from the Vardiman JW et al. The 2008 revision of the World Health Organization (WHO) classification of 
myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51. 
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Despite the improvement in overall survival,  ~30% of the pediatric patients relapse. The outcome 
of relapse  is poor, and only the ~30%–40% of patients survives 17, 18. Since the high frequency of 
treatment-related deaths (5%–10%) further intensification of chemotherapy seems no longer 
feasible 
19
. Therefore, knowledge on the molecular and genetic background is indispensable to 
detect novel, leukemia and patient-specific treatment targets 
1
. 
 
1.4 Molecular and Genetic Aberrations in Pediatric AML 
 
Despite the heterogeneous pattern of genetic lesions, AML is thought to arise from at least two 
classes of cooperating genetic events 
20
.  
Type I abnormalities result in increased of the proliferation and/or the survival of the leukemic cell. 
This type of mutations is often activating mutations of genes involved in signal transduction 
pathways, such as FLT3, KIT, N-RAS, K-RAS and PTPN11 
21
.  
Type II abnormalities impair differentiation and mainly result from genetic aberrations in 
hematopoietic transcription factors, due to, for instance, translocations t(8;21)(q22;q22)/AML1-
ETO and 11q23/MLL rearrangements or from mutations in genes, such as NPM1 and CEBPA 
7, 22-
26
. Accordingly to the “two-hits” model for leukemogenesis, the mutations conferring 
prosurvival/proliferative advantage (Type I) need to be associated with the mutations that impair the 
ability to differentiate of the hematopoietic progenitors for a complete outset of acute myeloid 
leukemia (Type II) 
25
. 
1.4.1 Proliferation and/or prosurvival aberrations (Type I mutations) 
 
Generally the type I mutations occur in genes encoding for proteins involved in proliferation and 
survival pathways (Figure 1 A, B). 
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(A) 
Pediatric Acute Myeloid leukemia 
Type II mutations 
 
Type I mutations 
 
(B) 
Cytogenetically Normal AML 
Type II mutations 
 
 
Type I mutations 
Figure 1. Distribution of Type I/II abnormalities in pediatric AML. (A) Cooperating Type I and Type II mutations in 
pediatric AML and (B) in cytogenetically normal AML. The circos plot depicts the frequency of the Type II mutations 
and co-occurrence of Type I mutations in patients with de novo pediatric AML. The length of the arch corresponds to 
the frequency of the Type II mutation and the width of the ribbon with the percentage of patients with a specific Type I 
mutation or a combination of Type I mutations. FLT3/ITD denotes FLT3 internal tandem duplication. Modified from de 
Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: From Biology to Clinical Management. J Clin Med. 
2015;4:127-49.   
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FLT3 mutations 
The Fms-like tyrosine kinase 3 (FLT3) is a member of the class III subfamily of receptor tyrosine 
kinases and it is activated by FLT3 ligand 
27
. FLT3 is expressed in early hematopoietic progenitor 
cells in the bone marrow 
27
. High FLT3 levels have been detected in acute myeloid leukemia 
(AML) 
28, 29,27, 30
. The most common mutation in AML is the internal tandem duplication (ITD) in 
the juxtamembrane domain of FLT3 with a 10-15% occurrence in pediatric patients
31
. FLT3-ITD 
serves as a prognostic marker since it positively correlates with higher blast counts, increased 
relapse rate, and worse overall survival 
30, 32, 33
. Several activating point mutations in the tyrosine 
kinase domain (TKD) have also been identified.
27
 
Acute myeloid leukemia cells show increased proliferation and survival, as well as impaired 
hematopoietic differentiation.
27 
FLT3-ITD or FLT3-TKD activation confers proliferative and 
survival advantages to cells
 27, 34
 by activating Src family tyrosine kinases (SFKs), the PI3K/Akt-, 
mitogen-activated protein kinase (MAPK) pathways, and, in the case of FLT3-ITD, also Stat5.
34
 
Moreover recently it has been demonstrated that FLT3 also blocks differentiation, at least 
partially, via p27 downregulation. 
35,
 
36
 
 
KIT activating mutations 
Kit, a proto-oncogene in a region on the long arm of chromosome 4 (4q11–4q13), encodes the SCF 
receptor (CD117) 
37
. Ligand independent activation of KIT is driven by mutations that could occur 
in the extracellular domain of the receptor, in transmembrane/juxtamembrane domain and in the 
activation loop of the tyrosine kinase domain. Deregulation of KIT, including overexpression and 
gain of function mutations, has been detected in several human cancers. The proto-oncogene KIT is 
expressed in approximately 80% of adult AML cases, and its expression is a reliable molecular 
marker of poor prognosis in AML
38, 39
. Moreover, KIT mutations are found in 25% to 30% of 
cases of adult core-binding factor (CBF)-AML, and in 19% of pediatric CBF-AML, which is 
genetically expressed by the presence of t(8;21)(q22;q22) or inv(16)(p13;q22) 
40
 
41
. 
 
RAS activating mutations 
RAS proto-oncogenes, including KRAS, NRAS, and HRAS, encode a membrane-localized G protein 
of 21 kDa, they regulate the growth and differentiation of many cell types. RAS proteins are located 
on the inner surface of the plasma membrane and act as molecular switches that transduce 
extracellular signals to the nucleus. It is inactive when bound to GDP and active when bound to 
GTP
42, 43
. RAS activation caused by its mutation giving rise to an abnormal protein resistant to GTP 
hydrolysis by GTPase leads to a constitutively active GTP-bound protein that stimulates a critical 
13 
 
network of signal transduction pathways that result in cellular proliferation, survival, and 
differentiation 
42-45
.  RAS  mutations at codons 12, 13, and 61 are common events in human 
cancers
45
. NRAS or KRAS mutations occur in ∼20% of AML specimens 46, and Ras signaling is 
activated by somatic mutations in the genes encoding the FLT3 and c-Kit receptor tyrosine kinases 
in an additional ∼25% to 40% of cases 44. 
 
PTPN11 mutations 
The PTPN11 gene encodes SHP-2, a cytoplasmic protein tyrosine phosphatase. Germline PTPN11 
mutations are the causative defect in Noonan syndrome, but somatic mutations have been described 
in juvenile myelomonocytic leukemia, acute lymphoblastic leukemia, and approximately 4% of 
children and adults with AML
47, 48
. Gain of function of SHP-2 contributes to leukemogenesis by 
upregulating the Ras-Erk and PI3K-Akt pathways leading to aberrant proliferation of myeloid 
progenitors 
49, 50
. Moreover, Somatic mutations in PTPN11 are found in about 35% of juvenile 
myelomonocytic leukemia cases 
51
. Approximately 4.4% of pediatric AML cases show PTPN11 
mutations and the 22% of these carry also mutation in FLT3 and RAS genes 
52
. The presence of 
PTPN11 mutation does not carry prognostic implications in AML, although robust data in 
combination with other cytogenetic abnormalities are lacking 
47, 53, 54,
 . 
 
AML with NPM1 mutations 
The nucleolar protein nucleophosmin 1 is involved in numerous cellular functions, such as 
ribosome biogenesis, DNA repair and regulation of apoptosis. Although it is a rather late event in 
leukaemogenesis, NPM1 mutations emerge as a distinct AML entity. Mutations result in aberrant 
localization of the protein to the cytosol. An N-terminal nucleolar localisation signal is disrupted, 
and an export signal is created instead. Mutations in the NPM1 gene are common genetic changes 
in both pediatric and adult AML, with a incidence of 5% - 10% and 35% respectively 
55
. In the 
absence of FLT3-ITD mutations, NPM1 mutations are associated with improved outcomes for 
patients with CN-AML, even in those older than 60 years. NPM1 mutations are associated with 
other recurrent genetic abnormalities, such as trisomy of chromosome 8, DNMT3A mutations, 
FLT3-ITD (40% of the time), FLT3-TKD (10–15%) and IDH mutations (25% of time) 56-58 . 
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Janus kinase 2 (JAK2) activation mutations 
The Janus kinase (JAK) family of nonreceptor tyrosine kinases are important mediators of 
cytokines and Grow Factor signaling, activating signal transducer and activator of transcription 
(STAT) proteins and other downstream signaling pathways that modulate cell cycling and apoptosis 
59
. STATs are constitutively activated in several solid tumors and hematological malignancies 
60-
62
. Gain-of-function JAK2 V617F mutations are common in myeloproliferative disorders 
63, 64  
(90% 
of polycythemia vera cases, 50% of essential thrombocythemia, and in about 70% of patients with 
AML secondary to other myeloproliferative disorders) but are rare in AML (1.6%)
 63,
 
65
. 
 
 
1.4.2. Cytogenetic abnormalities impaired myeloid differentiation (Type II mutations) 
The most common cytogenetic abnormalities (Type II) in children are t(8;21)(q22;q22), 
inv(16)(p13.1q22) (together referred to as core binding factor  (CBF)-AML), t(15;17)(q22;q21) and 
11q23/MLL-rearranged abnormalities (Figure 1A) 
26, 66-68
. Together, these account for 
approximately half of all pediatric AML cases, a much higher frequency than in adults. 
Translocations involving hematopoietic transcription factors often lead to dysregulated gene 
expression, either as a result of the fusion partner itself or the recruitment of different co-factors to 
the transcription complex 
1
. 
 
CBF (Core Binding Factor leukemia) 
CBF-AMLs, which account for approximately 23% of pediatric, contain chromosomal 
translocations or inversions that target the transcription factors RUNX1 (AML1) or CBFB 
69
. 
Normally RUNX1 and CBFB heterodimerize to bind DNA and recruit lineage defining 
transcription factors to regulate hematopoietic differentiation 
70
. The fusion products found in CBF-
AMLs [RUNX1-RUNX1T1/t(8;21)(q22;q22) or CBFB-MYH11/inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22)] block myeloid differentiation but are not sufficient to induce leukemia and 
both fusions requires secondary mutations, including those in the Ras pathway 
71-74
. Moreover, the 
AML1 gene is also involved in another translocation t(16;21) in which it results to be in-frame 
fused with the gene CBFA2T3 localized on chromosome 16. Interestingly, CBFA2T3 gene encode 
for a protein of the same family of ETO and, functionally, these two chimeric protein could be 
considered equal 
75
. Alterations of the CBF are prognostic markers of good prognosis, and a 
specific subtype of AML, known as core-binding factor AML (CBF-AML), has been define base on 
that. Nevertheless, the CBF-AML patients are predicted to have a good outcome as long as there are 
no other negative prognostic markers such as FLT3-ITD or KIT mutations 
76
. 
15 
 
 
CCAAT enhancer binding protein a (CEBPA) mutations 
Mutations in the differentiation-inducing transcription factor CCAAT enhancer binding protein a 
(CEBPA) are observed in 6–10% of all AML and 15–19% of CN-AML cases and commonly in 
association with del(9q) and in approximately 4% - 6% of pediatric AML 
23, 77, 78
. CEBPA is a 
critical transcription factor that controls gene expression during haematopoiesis 
79
. Importantly, 
only bi-allelic, not single, CEBPA mutations (BiCEBPAα) predicts an increased complete 
remission rate and favourable survival 
80, 81
. AML with a single CEBPA mutation is associated with 
survival rates similar to that of AML with wild-type CEBPA 
58, 82, 83
 Moreover BiCEBPα mutation 
is found to be stable and highly penetrant. Thus, the stability of biCEBPα supports its role in 
defining a distinct molecular and clinical subtype of AML 
84
. 
 
PML/RARα and acute promyelocytic leukemia 
PML/RARα traslocation involves the retinoic receptor-alpha gene (RARA) on chromosome 17 and 
the promyelocytic leukemia gene (PML) on chromosome 15. This aberrations is exclusively 
associated with the acute promyelocytic leukemia (APL). In APL, PML/RARα fusion protein 
actively recruits co-repressor complex, thus inducing a sustained transcriptional inhibition and 
resulting at functional level in a block of myeloid differentiation and increased self-renewal of 
leukemic progenitors.  As a consequence of these biologic properties PML/RARAα acts as a potent 
transcriptional repressor of retinoic acid signalling. Remarkably, over the 90% of PML/RARα-
positive cases could be successfully treated with all-trans retinoic acid (ATRA) that is able to 
induce the differentiation of this leukemic cells into mature granulocytes 
76,
 
85
. 
 
Mixed lineage leukemia (MLL) gene alterations 
Acute leukemia bearing an MLL-rearrangement (MLL-r) is a distinct leukemia subgroup that needs 
much attention. While the overall survival of acute leukemias in pediatric patients reaches about 
90%, MLL-r leukemia patients still display poor survival rates 
86
. MLL gene encodes a protein 
(500 kDa) which serves as a platform for the assembly of a multiprotein complex. The MLL 
complex influences gene transcription and chromatin by binding to target gene promoters, and 
reading and writing chromatin signatures.  
Based on data published in the literature, MLL-r AML patients display an ectopic genetic program 
caused by the overexpression of MEIS1/HOXA proteins 
87-89
. Overexpression of HOXA9 and 
MEIS1 is essential to drive the development and maintenance of acute myeloid leukemia. In the last 
years it has been developed a series of new inhibitors that can be potentially used to treat this 
16 
 
disease entity 
90-95
 and many of these is in clinical trial. All these drugs target either a druggable 
domain that is critical for the function of an MLL fusion or an associated protein 
96
. 
 
1.5 Acute megakaryoblastic leukemia 
 
Acute megakaryoblastic leukemia [AMKL or AML-M7 in the French–American–British (FAB) 
classification] is a subtype of AML 
15
, representing 3–5% of AML and affecting the megakaryocyte 
lineage. AMKL is higher prevalent in young children (median age approximately 1 year) than in 
adults (median age approximately 58 years).  
Pediatric AMKL is diagnosed as a  de-novo disease or in patients harboring constitutive trisomy 21 
[Downsyndrome (DS)] 
97
, who present a 500-fold increased risk to develop AMKL. The 90% of de-
novo AMKL harbor both numerical and structural chromosomal alterations, including hyperploids 
and complex karyotypes 
98
. Early cytogenetics and fluorescence in situ hybridization analyses 
identified the recurrent (1;22)(p13;q13) chromosomal translocation 
99-101
 and led to the 
identification of the OTT–MAL fusion oncogene 102, 103. OTT–MAL is specifically associated with 
childhood AMKL and fuses most of OTT and MAL coding regions. The OTT family was proposed 
to inhibit the RBPJ-dependent transcription of Notch pathway target genes
104
, which contributes to 
embryonic hematopoiesis 
105
 and controls the T-cell development 
106
 or erythro-megakaryocytic 
lineage commitment
107, 108
. MAL is a strong transcriptional coactivator of serum response factor 
(SRF) 
109
 through the recruitment of other epigenetic regulators such as ASH2 and SET1
110
. OTT–
MAL alters the transcription of SRF-dependent promoters in transient transactivation in vitro 
systems and the low frequency of additional mutations found in OTT–MAL AMKL patients 
suggests that OTT–MAL is sufficient for leukemogenesis in humans111. Other acquired 
chromosomal abnormalities (e.g., trisomy21, trisomy 19, monosomy 7) are also frequent in 
AMKL
112
. In  addition both MLL and NUP98 fusions and aberrant expression  of homeobox 
(HOX) are also associated with AMKL 
113
. Recently, high-throughput sequencing approaches 
discovered a novel recurrent fusion oncogenes: the CBFA2T3-GLIS2 fusion gene
111, 114-116
. 
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1.6. CBFA2T3-GLIS2 fusion gene 
 
CBFA2T3-GLIS2 also known as ETO2-GLIS2 is a fusion gene resulting from a cryptic inversion 
of the telomeric region of chromosome 16 leading the the 5’ portion of CBFA2T3 gene fused in-
frame to the 3’ region of GLIS2 gene (Figure 2).  
 
Figure 2.  Schematic representation of  fusion between exon 11 or exon 10 of CBFA2T3 and exon 3 or exon 2 of 
GLIS2. Modified from Masetti et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, 
cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013 
 
The incidence of CBFA2T3-GLIS2 (also known as CBFA2T3-GLIS2) is 17% and 8%  in pediatric 
non-Down syndrome acute megakaryoblastic leukemia (non-DS AMKL, FAB M7) 
114, 115, 117
 and in 
pediatric cytogenetically normal AML (CN-AML, in association with several FAB subtypes)
116
, 
respectively. The expression of CBFA2T3-GLIS2 is associated with grim prognosis in all the 
reports published so far 
116, 118
 (Figure 3). 
 
 
Figure 3. Probability of 5-year EFS in children with CBFA2T3-GLIS2 fusion transcript in CN-AML. EFS of 
CBFA2T3-GLIS2–positive patients (27.4%, SE 10.5) vs CBFA2T3-GLIS2–negative patients (59.6%, SE 3.6; P = .01). 
Modified from Masetti at al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically 
normal AML, not restricted to FAB M7 subtype Blood 2013 121:3469-3472. 
18 
 
 
CBFA2T3 is a member of the Eight Twenty One family of transcriptional co-factors that includes 
ETO and MTGR1. CBFA2T3 expression is essential for HSC maintenance and differentiation, and 
plays a critical role in the development of megakaryocyte-erythrocyte progenitors in vivo 
119, 120
. 
CBFA2T3 participates in high-molecular-weight complexes with several transcription factors 
(including TAL1, RUNX1, GATA, and ETS) that are able to both activate and repress gene 
transcription to control HSC commitment toward the erythroid and megakaryocytic lineages, 
depending on the cofactors found in these transcriptional platforms
121-124
. In particular, CBFA2T3 
represses the expression of erythroid genes 
124, 125
. During megakaryopoiesis, CBFA2T3 reportedly 
represses gene expression to inhibit terminal differentiation 
126
. 
The GLIS family zinc-finger protein 2 (GLIS2) is closely related to GLI and zinc-finger protein 
families. The CBFA2T3-GLIS2 fusion contains most of GLIS2 protein, including its DNA-binding 
domain, which comprises all five zinc-finger domains. GLIS2 is highly expressed in adult kidney, 
where it reportedly suppresses the Gli1- activated transcriptome and maintains homeostasis, and is 
mutated in human nephronophthisis 
128
.  
 Although GLIS1/2 factors have been proposed to support the pluripotent stem cell state 
129, 130
, their 
contribution to normal HSC biology is unknown. 
Different studies show that both CBFA2T3-GLIS2 and GLIS2 expression can increase self-renewal 
capacity in hematopoietic progenitors. In particular CBFA2T3-GLIS2 enhances self-renewal and 
inhibits differentiation, whereas the ectopic GLIS2 expression has a variable effect on self-renewal 
but  promotes megakaryocytic differentiation 
114
. 
Importantly, the activity of two transcription factors (GATA1 and ERG) previously involved in 
DS–AMKL leukemo-genesis is altered by CBFA2T3-GLIS2. GATA1 is strongly down-regulated 
as a result of both CBFA2T3 and GLIS2 functions, while the ETS-factor/ERG gene, located on 
chromosome 21, is strongly overexpressed primarily due to the GLIS2 moiety. Definitely, 
CBFA2T3–GLIS2 AMKL in a single event strongly increases ERG and downregulates GATA1 
(Figure 4). It was proposed that the level of deregulation of this balance is in part responsible for the 
aggressiveness of the disease. According to this hypotesis CBFA2T3–GLIS2 is rarely associated 
with mutations in coding sequences, suggesting it maybe sufficient to drive leukemogenesis 
111
.  
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A                                                                                            B 
 
                                
Figure 4. (A) In the normal megakaryocytic differentiation  CBFA2T3 (also known as ETO2) complex induces 
GATA1 expression and represses ERG expression. (B) ETO2-GLIS2 is a potent inducer of ERG expression and in the 
same time it is a repressor of GATA1. The deregulation of this balance between ERG and GATA1 is sufficient to block 
megakaryocytic differentiation and  to induce leukemia. (Modified from Thirant et al. 2017. ETO2-GLIS2 Hijacks 
Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia) 
 
1.7 Targeting Hedgehog pathway in AML  
 
The Hedgehog (HH) signalling pathway has diverse functions in animal development and tissue 
homeostasis. Dysregulation of this pathway has been implicated in several developmental 
syndromes and cancers 
131
. In mammals, the HH signaling cascade is initiated by one of three 
ligands: Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh) which bind to 
the transmembrane receptor Patched-1 (PTCH1). Without the presence of ligands, PTCH1 represses 
activation of the transmembrane protein Smoothened (SMO). Upon HH ligand binding, PTCH1 is 
internalized, resulting in relief and thus activation of SMO that transduces the signal to the family 
of Glioma (GLI) zinc finger transcription factors: GLI1, GLI2, and GLI3. GLI1 and GLI2 
predominantly represent transcriptional activators while GLI3 acts as transcriptional repressor 
132
 
(Figure 5). HH pathway has recently received much attention for its implication in advanced 
haematological malignancies and acquired drug resistance in AML with poor prognosis. Interesting 
it has been demonstrated that the expression of GLI proteins can correlate with poor prognosis in 
AML and with decrease of DNA methylation in MDS
133
. Currently there are small molecules that 
can inhibit HH pathway at different levels (Figure 5) and in particular the SMO inhibitor are in 
many clinical trials in combination with other conventional drugs in different types of cancer 
including haematological malignancies (NCT02073838 NCT01842646, NCT01841333, 
NCT01546038, NCT02367456).  
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It is noteworthy that in a phase 2 trial with untreated AML and high-risk MDS patients, low dose 
Ara-C chemotherapy in combination with glasdegib improved overall survival when compared to 
chemotherapy only 
134
. 
Moreover HH pathway can be activated through other pathway including K-Ras, TGF-β, PI3K-
AKT, and PKC-α that can be positive regulate GLI protein transcriptional activity 135, 136. Based on 
these obseravtions, direct inhibition of GLI is a promising option, particularly in settings of SMO-
independent GLI activation.  
 The GANT61 is a small molecule inhibiting DNA binding of GLI family proteins, and it is largely 
used in preclinical studies 
132, 137
. It has been reported that GANT61 showed a potent effect on the 
transcription activity of GLI proteins, binding directly GLI Zing Finger domain and blocking their 
binding to DNA 
138
 (Figure 5). 
 
 
 
 
Figure 5. Canonical and non-canonical activation of HH pathway by oncogenic mechanisms. The figure shows the 
target drugs that could inhibit HH pathway at different level. From: (Aberger F et al. Acute myeloid leukemia - 
strategies and challenges for targeting oncogenic Hedgehog/GLI signaling). 
  
21 
 
2. Aim 
 
The overall aim of this research project was to investigate the potential benefit of the GANT61 (a 
GLI inhibitor) in the subgroup of AML with the CBFA2T3-GLIS2 fusion gene. Indeed, in the last 
year different studies described the mechanism of CBFA2T3-GLIS2 to induce leukemia 
transformation. 
GLIS2 and GLI proteins family shares a lot of homology of the zinc finger domain (ZFD) 
indispensable for the DNA binding. Due to the highly homology between the GLIS2 protein and 
members of the GLI family, the final effectors of classic Hedgehog pathway
132, 139
, we hypothesized 
that the GANT61, a small molecule inhibiting the binding of GLI to DNA
138
, might be used to 
specifically target the CBFA2T3-GLIS2 fusion in pediatric AML. 
Because no model of transformation of normal human cells with CBFA2T3-GLIS2 exist, the second 
aim of this project was to set-up a human model of  induced pluripotent stem cells (iPSC) 
technology expressing the CBFA2T3-GLIS2 fusion gene. The iPSC technology presents 
considerable advantages over classical in vitro models, as the immortalized tumor-derived cell lines 
may contain additional abnormalities due to their derivation, and thus may not properly represent 
patient’s leukemic cells. Moreover, the iPSCs are capable of self-renewal, and above all can be 
differentiated in all cell types including hematopoietic lineage.  
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3. Materials and Methods 
 
3.1. Cell Lines and reagents 
 
Human AML cell lines (M07e, HL60, NOMO1, Kasumi-1, MOLM-13, THP-1, OCI-AML3) were 
obtained from DSMZ; WSU-AML cell line was kindly provided by St. Jude Children's Research 
Hospital, Memphis, TN, USA. WSU-AML, HL60, NOMO1, MOLM13, THP1 and KASUMI-1 
were grown in RPMI 1640 (Lonza), M07cells were grown in Iscove Medium Dulbecco’s modified 
(IMDM) (Sigma) and OCI-AML3 in Alpha-MEM (Lonza). All culture media were supplemented 
with 10% Fetal Bovine Serum (EuroClone), 2mM L-glutammine (GIBCO) and 100 U/ml 
penicillin/streptomycin (GIBCO). Primary cells were obtained from two AML pediatric patients, 
FAB M7 (AMKL1) positive to fusion gene CBFA2T3-GLIS2 and FAB M4 negative for the same 
translocation, respectively. Primary cells were grown in Chang Marrow (Technogenetics). 
3.2 Cell viability assay 
 
To test the effect of GANT61 (Merck Millipore), cell lines were cultured for 72 hours in the 
presence of increasing drug concentrations from 0.1 µM to 100 µM, and cell viability was assessed 
using the WST1 (4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate), 
cell proliferation kit (Roche Diagnostic, Basel, Switzerland), according to manufacturer’s 
instructions. The curve and IC50 were calculated by non-linear dose-response regression with 
Graphpad Prism software (San Diego, CA, USA). Statistical analyses were performed using 
Student’s t test at a significance level of p <0.05 (GraphPad Prism Software). 
3.3 Cell cycle analysis and apoptosis assay 
 
Cell cycle analysis was performed staining cells with propidium iodide (PI) solution (PI 50 μg/ml; 
0.1% sodium citrate; 0,1% Triton X-100) according to standard protocol 
140
 and after 48 hours of 
GANT61 treatment. 
To assess the extent of induced apoptosis, flow cytometric analysis of Annexin V–FITC/propidium 
iodide (PI)-stained samples was performed after 24 hours of treatment with GANT61 and in basal 
condition, following manufacturer's instruction (Annexin-V-FLUOS Staining Kit, Roche 
Diagnostics, Monza, Italy). The samples were analyzed by a FACS Canto flow cytometer (Beckton 
Dickinson, Franklin Lakes, NJ). Apoptotic cells were identified as Annexin V-positive, PI-negative 
cells. 
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3.4 Western Blotting 
 
Western blotting analysis was performed using standard procedures after 48 hours of treatment with 
GANT61. Cells were lysed using M-PER Mammalian Protein Extraction Reagent, supplemented 
with the Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific Inc., Rockford, IL, 
USA). GLIS2 antibody was purchased from Santa Cruz Biotechnology (Heidelberg, Germany), 
GLI1 antibody was purchased from Cell Signaling Technology and GLI2 was purchased from 
Biorad. Secondary antibodies were purchased from Cell Signaling Technology. Densitometry 
scanning of the bands was performed using a Chemidoc 810 Imager with the appropriate software 
(UVP, Upland, CA, USA). 
 
3.5 Quantitative PCR and gene expression.  
 
Cell lines (M07e, WSU-AML) and primary cells (AMKL1) positive to CBFA2T3-GLIS2 fusion 
gene were grown in presence of GANT61 20 µM or vehicle (DMSO) for 48h. Total RNA was 
extracted by RNeasy spin column method (Qiagen). 250 ug of RNA was reverse transcribed to 
single-stranded cDNA using the Transcriptor first strand cDNA synthesis kit (Roche Diagnostics) 
with oligo-dT primers (2.5 μM). qRT-PCR was performed with FastStart Sybr Green (Roche 
Diagnostics) on the LightCycler 480 apparatus (Roche Diagnostics) using specific primers for 
BMP2, GLIS2. DDCt method was used to quantify gene expression levels relative to two 
housekeeping genes, YWHAZ and ATP5B. Quantitative RT-PCR primer sequences were as 
follows: 
Gene expression profile was assessed using GeneChip Human Transcriptome Array 2.0 
(Affymetrix, Santa Clara, CA, USA). Microarray target sample processing, target hybridization, 
washing, staining and scanning steps were completed according to manufacturer's instructions 
(Affymetrix).  
Data normalization and summarization was  performed using the RMA (Robust Multi-Array 
Average) method 
141
. Before proceeding with differential expression computation, the dimensions 
of the dataset were reduced by filtering out genes whose IQR is smaller than the 10th percentile of 
global IQR and whose expression level is below 5 in more than two samples. To score the 
differences of expression between the two conditions, we used the moderated t-statistics for paired 
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samples (implemented in limma package) with a significance level α =0.05.  Differentially 
expressed genes were then classified as upregulated if logFC>1 and downregulated (logFC< 1). 
 
3.6 ChIP analysis 
 
ChIP analysis was performed using the chromoFlash High sensitivity ChIP kit (Epigentek). In brief, 
1 × 10
6
 of WSU-AML and M07e cell lines were fixed with 1% formaldehyde, lysed, and sonicated 
(Bioruptor Pico sonication device, Diagenode). Sheared chromatin was immune-precipitated for 3h 
using the following antibodies: anti-CBFA2T3 (Abcam), and normal rabbit non-immune IgG 
(Epigentek). One tenth of the sheared chromatin (Input) was used as a reference for the quantitative 
PCR analysis using the primers proximal NCAM1 promoter, DNMT1 and DNMT3B promoter with 
FastStart Sybr Green (Roche Diagnostics) on the LightCycler 480 apparatus (Roche Diagnostics). 
 
3.7 Cloning of CBFA2T3-GLIS2 fusion gene 
 
CBFA2T3-GLIS2-GFP was cloned through in fusion strategy (In-Fusion® HD Cloning Kit, Takara 
Bio, USA) into AAVS1-SA-2A-puro-pA driven by CD43 promoter vector available in Gustave 
Roussy institute. First, CBFA2T3-GLIS2 tagged with GFP was amplified from a  lentiviral vector 
already described in Thirant et al 2017
112
, with specific primers containing an overlap region on the 
vector AAVS1-SA-2A-puro-pA. Second, the PCR insert was cloned following the in fusion kit 
manifacture’s instruction. The in-fusion reaction was transformed in XL10-Gold Ultracompetent 
cells (Agilent). The other two vectors encoding the two Zing Finger proteins specific for AAVS1 
locus left and right arms were available in Gustave Roussy institute. 
 
3.8 iPSC Culture 
 
iPSC derived from healthy donor were avaliable in iPSC platform, Gustave Roussy institute. iPSC 
were cultured in Essential 8 medium (ThermoFisher) and in vitronectin (Thermofisher) coated 
wells. iPSC were passed every 3-4 days in DPBS/0.5mM EDTA Ultrapure (Thermofisher). 
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3.9 iPSCs genome editing using AAVS1 zinc-finger nucleases 
 
The wild-type iPSC were treated with Triple 1x (Thermofisher) to make single cells. 0.8x10
6 
 of 
single cells were electroporeted with CBFA2T3-GLIS2 donor construct in association with the 
vectors encoding for Zing Finger, using Nucleofector 2B and Stem cell kit (Lonza). Electoroporated  
iPSC were plated in vitronectin coated  plate in presence of 10µM of Y27632 (Miltenyi Biotec). 
Three days later the electroporated  iPSC were selected with puromycin (0.5 μg/mL) for 48h. After 
1 week 23 individuals clones were picked, expanded and screened for correct integration at the 
AAVS1 locus using PCR. 
 
3.10 Characterization of iPSC, knock-in with CBFA2T3-GLIS2 
 
Wild-type iPSC and iPSC from clone 10 with CBFA2T3-GLIS2  knock-in were dissociated in single 
cells through Triple 1x  treatment. 1x10
6
 cells were plated in Nunclon™ Sphera (ThermoFisher) to 
induce embryoid bodies development. Embryoid  bodies (EB) were grown in Essential 6 Medium 
(ThermoFisher) at least for 24 days replacing medium every 3 days. RNA from embryoid bodies 
were extracted after 17 days and 24 days and the expression of markers from the three layers upon 
EB differentiation were tested for iPSC CTRL and iPSC clone 10.  
The list of all primers used for PCR and RT-PCR is reported in Table 3. 
 
 
Table 3 
 
Real-Time PCR 
Locus Forward 5’-3’ Reverse 5’-3’ 
GLIS2 GAGGTTTCAACGCCAGGTACA GCAGACGTAGGGCTTCTCAC 
BMP2 GACTGCGGTCTCCTAAAGGTCG CTGTTTCAGGCCGAACATGC 
ATP5B GTCTTCACAGGTCATATGGGGA GTCCCACCATATAGAAGG 
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YWHAZ AAAAACAGCAGATGGCTCGAGAA GTGAAGCATTGGGGATCAAGAAC 
CBFA2T3-
GLIS2 
CATCAACCAGCAGGAGGACT ACTTGTCCTTGGGAGGGGTA 
GAPDH CCAATATGATTCCACCCATGGC CTTGATTTTCGAGGGATCTCGC 
NeuroD1 GAGCACGAGGCAGACAAGAAG CCCCCGTTCCTCAGTGAGT 
HAND1 AACTCAAGAAGGCGGATGG AGGGCAGGAGGAAAACCTT 
GATA 4 GCTATGCGTCTCCCGTCAG GTGACTGTCGGCCAAGACC 
NANOG CCATCCTTGCAAATGTCTTCTG CTTTGGGACTGGTGGAAGAATC 
Oct4 GCAGCAGATCAGCCACATC CTTGATCGCTTGCCCTTCT 
CHIP analysis 
NCAM1 GCATCTGCCTCCCTGTCTCT CTCGCAACTCGGAGATCCTT 
DNMT1 ACTCAAGGGCTCTCACAAA CGAGGCATTCATTCATTCAT 
DNMT3B GGGCTACAAGGGGAGT3 GCTCGGAGCGTCCAC 
 
PCR screening 
AAVS1 locus  
Integration 
TCTCTTCCGCAT 
TGGAGTCGCTTTAA 
ACCGTGGGCTTGTACTCGGTCAT 
AAVS1 locus  
Endogenous 
CCCCTATGTCCACTTCAGGA CAGCTCAGGTTCTGGGAGAG 
Primers for in-fusion cloning reaction 
CBFA2T3-
GLIS2-GFP 
AATTCCGCCAACCGGCCACCATGC
CGGCTTCAAGACTGAG 
GAGTGAATTCACGCGTTTACTTGTACAGCTCGTC
C 
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3.11 Differentiation of iPSC into hematological lineage 
 
Three clone with CBFA2T3-GLIS2 and CTRL iPSC were induced to differentiate into 
hematological lineage using 2D co-culture system on matrix adapted from Chou S et al. 
142
. Briefly 
3-4 colonies of each iPSC were picked and put into Geltrex (Thermofisher) coated wells in 
Essential 8 medium. In the next days we changed medium in StemPro34 enriched with 1X 
penicillin/streptomycin (PS, GIBCO), glutamine (2 mM), ascorbic acid (50 μg/ml, Sigma) 
monothioglycerol (MTG, 15 mM, Sigma), BMP4 (5 ng/mL) and VEGF (50 ng/ml) and CHIR (930 
ng/mL) for the first 2 days. The medium was replenished and supplemented until day 18 with a 
sequential cytokine cocktail, as shown in Table 4.  Hematopoietic differentiation of iPSC was then 
assessed at day 13, 15 and 18 using flow cytometry analyses for hematopoietic progenitors (CD34, 
CD43) and megakaryocytic  markers (CD41, CD42 and CD61). All data were analyzed with 
FACSCantoII or Fortessa with FACS Diva software (BD Biosciences). Antibodies were purchased 
from BD or eBioscience. 
 
Table 4 
 BMP4 CHIR VEGF bFGF SCF Flt3L TPO IL6 
 
Day 0 
 
5ng/mL 
930 
ng/mL 
 
50ng/mL 
     
Day 1 5ng/mL  50ng/mL 20ng/mL     
Day 4    15ng/mL 5ng/mL     
Day 6   50ng/mL 50ng/mL 50ng/mL 5ng/mL   
Day 7   50ng/mL 50ng/mL 50ng/mL 5ng/mL 50ng/mL 10ng/mL 
Day 8   50ng/mL 50ng/mL 50ng/mL 5ng/mL 50ng/mL 10ng/mL 
Day 11   50ng/mL 50ng/mL 50ng/mL 5ng/mL 50ng/mL 10ng/mL 
Day 13   50ng/mL 50ng/mL 50ng/mL 5ng/mL 50ng/mL 10ng/mL 
Day 15   50ng/mL 50ng/mL 50ng/mL 5ng/mL 50ng/mL 10ng/mL 
Day 18   50ng/mL 50ng/mL 50ng/mL 5ng/mL 50ng/mL 10ng/mL 
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3.12 Methylcellulose culture 
To test self-renewal properties CD43+ hematopoietic cells derived from iPSC differentiation were 
sorted with Fortessa and cultured in methylcellulose (H4230, StemCell Technologies) enriched with 
Flt3L 10ng/ul, G-CSF 20ng/ul, IL3 10ng/ul, IL6 10ng/ul, SCF 25ng/ul, TPO 10ng/ul, GM-CSF 
10ng/ul. All cytokines used were purchased from Peprotech, UK. Cells were replated every 7 days 
for 4 weeks. 
 
3.13 Culture of hematopoietic progenitors in liquid culture and treatment with GANT61 
To test the proliferation properties of hematopoietic progenitors we cultured the CD43+ sorted cells 
with and without CBFA2T3-GLIS2 in SP34 (Thermofisher) enriched with Flt3L 10ng/ul, G-CSF 
20ng/ul, IL3 10ng/ul, IL6 10ng/ul, SCF 25ng/ul, TPO 10ng/ul, GM-CSF 10ng/ul. After 2 days and 
10 days we counted the cells number using trypan Blue method. To the test the sensitivity of 
hematopoietic cells with CBFA2T3-GLIS2 fusion gene we treated the cells with three 
concentrations of GANT61: 8uM, 4uM and 2uM. After 48h we counted the abosolute number of 
the cells.  
3.14 DNA/RNA extraction and RT-PCR. 
 
DNA and RNA were isolated using the RNeasy Mini and All prep DNA/RNA Micro Kit (Qiagen) 
and quantified by NanoDrop (ThermoScientific). Reverse transcription was done with SuperScript 
II from Invitrogen. Q-PCR for CBFA2T3-GLIS2 was performed using SYBR Select master mix 
(Applied Biosystems) on 7500HT Fast Real-Time PCR System (Applied Biosystems) following 
manufacturer's recommendations. All Primers used were reported in Table 3 . The GATA3 and 
ERG expression was tested with TaqMan  probe (AppliedByiosystem).GATA3: Hs00231122, 
ERG: Hs01554629.  
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4. Results 
 
4.1 CBFA2T3-GLIS2-positive cells are sensitive to GLI1/2 inhibitor 
 
To test the effect of GANT61 on cell proliferation, we treated two AML cell lines positive for 
CBFA2T3-GLIS2 fusion with increasing concentration of GANT61 for 72h, and, then, we assessed 
the viability through WST1 assay. Both cell lines showed a marked sensitivity to the inhibitor with 
a strong reduction of cell proliferation and IC50 ranging between 10 µM and 15 µM (Fig. 6A). 
In contrast, GANT61 had lower effect on AML cell lines that do not express the CBFA2T3-GLIS2 
fusion, suggesting a specific effect of this inhibitor on the chimeric transcription factor. Similar 
results were obtained on primary leukemia cells isolated from AML patients (Fig.6B), where the 
IC50 of GLIS2-positive leukemia cells is 13.63 µM and that of other primary cells is 41.59 µM.  
 
 
Figure 6. A) IC50 of CBFA2T3-GLIS2 and negative cell lines 72h after GANT61 exposure, B Dose-response curves 
after 72h of GANT61 treatment of primary cells derived from patients with acute myeloid leukemia either positive or 
negative for CBFA2T3-GLIS2 fusion gene . *= p value < 0.05     
 
In order to further investigate the mechanism of action of  the GANT61, we evaluated the induction 
of apoptosis in AML cell lines after 24h of treatment. The cytometric analysis indicated that the 
GANT61 efficiently induced apoptosis in the CBFA2T3-GLIS2-positive cells with an increase of 
about 30% of cells positive to Annexin V in comparison to the untreated cells (Fig. 7). On the other 
hand, the HL60 cell line, which lacks CBFA2T3-GLIS2 fusion gene, did not show any significant 
increase of Annexin V positive cells (Fig. 7).   
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Figure 7. Flow cytometric analysis of Annexin V-FITC/PI stained AML cell lines treated for 24 h with 20 µM of 
GANT61. The percentages of early apoptotic cells (Annexin-V FITC
+
/PI
−
, lower right quadrant) and late 
apoptotic/necrotic cells (Annexin-V FITC
+
/PI
+
, upper right quadrant) are indicated. NT: sample treated with vehicle 
alone (DMSO). 
 
Moreover, cell cycle analysis showed an increasing number of CBFA2T3-GLIS2-positive cells 
(WSU-AML and M07e) in G0/G1 phase, and a decrease number of the cells in S and G2/M phases 
(Fig. 8).  
 
 
 
Figure 8. Cell cycle analysis. Flow cytometric analysis of PI-stained AML cell lines positive to CBFA2T3-GLIS2 
fusion gene after 48 h of treatment with 20 µM GANT61. NT: sample treated with vehicle alone (DMSO).  
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4.3 GANT61 downregulates expression of GLIS2 protein 
 
Since in the classic Hedgehog signaling pathway several target genes involved in feedback 
mechanisms (HHIP, PTCH1, GLI1) have been described, we hypothesized that CBFA2T3-GLIS2 
chimeric protein could regulate wild-type GLIS2 protein with the same feedback mechanism. Thus, 
we assessed the effect of GANT61 on the expression of GLIS2 protein in two cell lines (M07e, 
WSU-AML) using GLIS2 antibody.  Western blotting analysis confirmed the presence of chimeric 
protein, but, unexpectedly, showed also the presence of wild-type GLIS2. These results may 
indicate the role of the fusion protein in regulating wild-type GLIS2. Following treatment, the 
expression of both proteins were decreased with respect to untreated samples, suggesting that the 
GANT61 treatment targeted not only CBFA2T3-GLIS2 fusion protein, but also wild-type GLIS2 
expression (Fig. 9). 
 
 
Figure 9.  Western blot analysis showing the decrease of GLIS2 protein and CBFA2T3-GLIS chimeric protein in 
samples treated with 20 µM Gant61. Thirty micrograms of protein were blotted to each lane. Antibody to β-actin served 
as a loading control. Molecular weights are indicated at right. The Relative Induction (Rel Ind) is the amount of protein 
present in treated samples relative to untreated cells after normalizing to β-Actin density. NT, untreated cells. One 
representative of three independent experiments is shown.  
 
The known targets of GANT61 are GLI1 and GLI2 proteins, the final effectors of Hedgehog 
classical pathway. Therefore, as shown in figure 10 GLI1/2 proteins were expressed at low level in 
cell lines with GLIS2 translocation (M07e and WSU-AML) and the treatment with GANT61 did 
not affect their expression (Fig. 10). 
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Figure 10. Western blotting analysis of GLI1/2 protein in cell lines positive and negative for GLIS2 fusion gene treated 
for 48h with 20 µM GANT61. 
 
 
4.5 Treatment with GANT61 downregulates expression of HH and BMP signaling target 
genes 
 
Since the expression of CBFA2T3-GLIS2 fusion has been reported to be associated with 
upregulation of both HH and BMP signaling, as well as with an increase of expression of target 
genes of these pathways, such as BMP2 and GLIS2, we performed a qPCR analysis to assess the 
molecular effects of GANT61. As shown in figure 11A, treatment with GANT61 in WSU-AML 
and M07e cell lines, as well as in primary leukemia cells from the patient harboring the CBFA2T3-
GLIS2 fusion (AMKL1), led to a significant reduction of the expression of BMP2 and GLIS2. In 
order to fully characterize the effect of GANT61 treatment on whole transcriptome profile of 
CBFA2T3-GLIS2-positive cells, gene expression was assessed by microarray analysis. The 
expression profile confirmed the overexpression of GLIS2 and the activation of major Hedgehog 
mediators in untreated cell lines and primary leukemia cells expressing CBFA2T3-GLIS2. 
Moreover, following GANT61 treatment, the expression of target genes of CBFA2T3-GLIS2, such 
as CRISP3, GATA3, H2AFY or NCAM1 (CD56) was significantly downregulated (p<0.05) (Fig 
11B). Besides demonstrating the inhibition of GLIS2 pathway, we were able to identify additional 
genes that were downregulated by the treatment with GANT61 (p<0.05) (Fig. 11B). Among them, 
genes involved in cell proliferation (KIF14, MELK, MCM10, NUF2), regulation of cell cycle 
(CCNA2, CDKN3, CDC7, PRC1), genomic stability (BRCA1, BRCA2), and epigenetic regulators 
namely DNMT1, DNMT3B were present.  
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Figure 11 A) Quantitative PCR of selected mediators of GLIS2 pathway after 48h treatment of GANT61.  *= p value < 
0.05    **= p value < 0.01 ***= p value < 0.001. B) Hierarchical clustering of genes differentially expressed between 
untreated and treated AML leukemia blast cells and cell lines,  with a p value<0.05 
 
4.6 CBFA2T3-GLIS2 chimeric protein regulates DNMT1 and DNMT3B expression 
 
Gene expression analysis revealed downregulation of genes involved in epigenetic regulation, such 
as DNMT1 and DNMT3B. To assess if these genes could be direct transcriptional targets of 
CBFA2T3-GLIS2, we performed chromatin immunoprecipitation (ChIP) analysis using a 
CBFA2T3-specific antibody on WSU-AML and M07e cell lines. Quantitative PCR was then 
performed on immune-precipitated DNA using several primer pairs located in the proximal 
NCAM1, DNMT1 and DNMT3B promoter. Specific around fivefold enrichment was observed at 
the proximal promoter of these genes in WSU-AML and M07e cell lines expressing the CBFA2T3-
GLIS2 fusion gene. These data suggest that the CBFA2T3-GLIS2 fusion protein directly binds to 
the proximal promoter of DNA methyltransferase genes, regulating positively their expression (Fig. 
12). 
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Figure 12. ChIP analysis, performed on WSU-AML cell line has shown around five-fold enrichment of chimeric 
protein on DNMT1, DNMT3B and NCAM1 promoter. *= p value < 0.05    **= p value < 0.01 ***= p value < 0.001. 
 
 
4.7 iPSC engineered with CBFA2T3-GLIS2 maintain the pluripotent properties 
 
To study the biological effect of the CBFA2T3-GLIS2 fusion gene in megakaryocytic cells we set 
up an induced pluripotent stem cells (iPSC) model.  
To this aim we used an iPSC derived from healtoy donor engineered with CBFA2T3-GLIS2 fusion 
gene in AAVS1 locus. First of all CBFA2T3-GLIS2 cDNA tagged with the green fluorescent 
protein (GFP) driven by human CD43 promoter was cloned in AAVS1 SA-2A-puro-pA donor and 
the fusion gene was introduced in AAVS1 locus through Zing finger mediated recombination (Fig 
13).  
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Figure 13. Gene editing strategy. The constitutively active AAVS1 “safe harbor” locus is shown on the top line and the 
targeting construct is shown below. cDNA expression cassettes driving expression of CBFA2T3-GLIS2 cDNA tagged 
with GFP under the CD43 promoter were inserted by zinc finger-mediated homologous recombination into intron 1 of 
AAVS1. HA, homologous arms left (L) and right (R); SA-2APuro-PA, puromycin drug resistance cassette. 
 
After Puromycin selection we identified 23 clones with homozygous integration. 
From iPSC wild-type and iPSC from clone 10 we induced Embryoid bodies development and 
spontaneous differentiation into the three embryonic layers. The embryoid bodies were maintained  
in culture and RNA was extracted after 17 days and 24 days  to test expression of the three 
embryonic layers markers. The three embryonic layers were present in embryoid bodies as shown 
by expression of NeuroD1 for the neuroectoderm layer, Hand1 for mesoderm and GATA4 for 
endoderm (Figure 14). Moreover the expression of NANOG and Oct4, two markers of the 
pluripotent properties, decreased (Figure 14). These results demonstrated that iPSCs engineered 
with CBFA2T3-GLIS2 mantain pluripotent properties. 
 
A                                                                          B 
                 
 
 
Figure 14. Expression of genes specific for the three embryonic layers at day 17 (A) and at day 24 (B) after 
spontaneous differentiation of embryon body. 
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4.8 Expression of CBFA2T3-GLIS2 in human hematopoietic cells obtained from iPSC 
recapitulates several molecular features of human pediatric AMKL 
 
Three independent iPSC clones were amplified and subsequently differentiated into hematopoietic 
progenitors and then into megakaryocytes using a 2D co-culture system on matrix and compared to 
control iPSC. At day 18 of differentiation we collected the sovranatant containing hematologic 
progenitors and we extracted RNA to check in qPCR CBFA2T3-GLIS2 expression and several 
recently characterized direct targets of the fusion: ERG and GATA3 
114
. 
CBFA2T3-GLIS2 was expressed in hematologic lineage in all clones tested, at the mRNA level 
(Figure 15A). The fusion protein was also expressed as shown by expression of GFP in 
fluorescence microscopy (Figure. 15B).  Furthermore the expression of the genes ERG and GATA3 
were increased in CBFA2T3-GLIS2 clones (Figure 15C, 15D). 
These results demonstrated  that iPSC engineered with CBFA2T3-GLIS2 fusion gene reproduce the 
expression pattern of this leukemia subtype. 
 
 
Figure 15. Expression pathway of hematopoietic cells derived from iPSC differentiation. (A) CBFA2T3-GLIS2, (B) 
expression of  CBFA2T3-GLIS2 protein tagged with GFP, (C) ERG, (D) GATA3. Statistical significance is indicated as 
p values   * *p<0.01. *p<0.05. 
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4.9 CBFA2T3-GLIS2 induces aberrant differentiation in megakaryocytic cells 
 
Hematopoietic differentiation of iPSC was then assessed at day 13, 15 and 18 using flow cytometry 
analysis for progenitors (CD34 and CD43) and  megakaryocytic markers (CD41, CD42 and CD61).  
The CD43+ hematopoietic population in CBFA2T3-GLIS2 cells was composed of a higher 
percentage of CD41+CD42+ megakaryocytic cells than CTRL cells. Therefore we observed some 
strong different alterations in different populations of cells (Figure 16H), but in particular a 
progressive accumulation of an abnormal population expressing low level of CD41 and CD42 never 
detected  in the control conditions. Furthermore the integrin CD61, normally associated with CD41 
in a calcium-dependent heterodimeric complex, had lower expression on CBFA2T3-GLIS2 
megakaryocytic cells compared to controls at day 15 (Figure 16 D, E) and at day 18 (Figure 16 F, 
G). The low expression of CD61 was more evident in the abnormal population CD41
low
CD42
low 
in 
comparison with CTRL megakaryocytic cells (Figure 16E, 16G). 
Together these data indicated that CBFA2T3-GLIS2 enhances development of aberrant human 
megakaryocytic deregulating expression of markers CD41, CD42 and CD61.  
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Figure 16. A) Flow cytometry analysis of megakaryocytic markers (CD41,CD42, CD61) markers in CTRL and clone 
expressing CBFA2T3-GLIS2 fusion  gene at day 13, 15 (B,D,E) and 18 (C,F,G).  
(D,E) Expression of CD61 at day 15 gated respectively in CD41+CD42+ and in CD41
low
CD42
low
 population.  
(F,G) Expression of CD61 at day 18 gated respectively in CD41+CD42+ and in CD41
low
CD42
low
 population. 
(H) Percent number of different  populations  detected in flow cytometry analysis in hematopoietic cells derived from 
iPSC differentiation. 
Statistical significance is indicated as p-value (Student’s t-test): **p<0.01. *p<0.05.  
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4.10 CBFA2T3-GLIS2 enhances proliferation and self-renewal of progenitors hematopoietic 
cells 
 
To test the capacity of self-renewal of progenitor hematopoietic cells with CBFA2T3-GLIS2 we 
sorted the hematopoietic cells CD43+ at day 15 of differentiation and we cultured them in 
methylcellulose as well as in  liquide culture enriched with specific hematopoietic cytokines. 
For methylcellulose we counted the colonies and replated the cells every  seven days (Figure 17A). 
As early as at day 7 there were more colonies in CBFA2T3-GLIS2 cells than hematopoietic cells 
from CTRL (Figure 17B). Moreover the morphology of colonies in CBFA2T3-GLIS2 was more 
dense in number than CTRL probably due to the high proliferation induced by fusion gene (Figure 
17C). 
In the second replate, after 7 days the CTRL lost the capacity to make colonies while CBFA2T3-
GLIS2 cells maintained proliferation properties until forth passage (Figure 17B). 
 
 
 
Figure 17. (A) Experimental design to test the self-renewal capacity in methylcellulose experiments (B) Ratio of 
colonies number upon serial replating of CTRL and CBFA2T3-GLIS2 hematopoietic cells as means ± SEM (duplicate 
performed in 2 independent experiments). Cells were replated every 7 days for 4 weeks. (C) Morphology of colonies 
between P1 and P2. P1; passage 1; P2 passage 2; P3 passage 3. 
 
 
As the methylcellulose culture we tested megakaryocytic markers and proliferation properties also 
in liquid cultured. To this aim we maintained CD43+ hematopoietic cells in culture for 4 days and 
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10 days. As shown in figure 18 we confirmed the presence of the aberrant megakaryocytic 
population with low expression of CD41 and CD42 markers (Figure 18A). Moreover the 
proliferation of CBFA2T3-GLIS2 hematopoietic cells was clearly higher than hematopoietic CTRL 
cells (Figure 18 B, C). Furthermore preliminary morphology studies demonstrated that in liquid 
culture only the CTRL cells were induced to acquire pro-platelet morphology as shown in Figure 
18D (Figure 18D).   
These results indicated that this fusion gene is sufficient to increase cell proliferation, self-renewal 
properties and block of platelets differentiation  in-vitro.  
 
Figure 18. (A) Expression of CD41 and CD42 in hematopoietic cells derived from iPSC differentiation (B) Ratio 
number of  CD43+ hematopoietic cells after 4 days and (C)10 days of sorting . (D) Morphology analysis of CD43+ 
hematopoietic cells  in  the CTRL and in the (E) CBFA2T3-GLIS2 cells .  Statistical significance is indicated as p values 
(Student’s t-test): *p<0.05.  
 
41 
 
4.11 The GANT61 inhibits the proliferation of CBFA2T3-GLIS2 hematopoietic cells derived 
from iPSC differentiation  
 
To test the capacity of GANT61 to inhibit proliferation we treated hematopoietic cells with or 
without CBFA2T3-GLIS2 in liquid culture. We exposed the hematopoietic cells at low  
concentration of GANT61. The number of cells after 48h of treatment revealed that GANT61 
inhibited proliferation of hematopoietic cells with CBFA2T3-GLIS2 expression. In particular at  
2uM of GANT61 concentration the mortality of cells with fusion gene was around 50% in 
comparison with any effect in the CTRL (Figure 19). 
This result suggests a possible effect of the GANT61 in this particular subgroup of AMKL. 
 
 
 
 
Figure 19. Absolute number of CTRL and CBFA2T3-GLIS2 hematopoietic cells treated with different concentrations of 
GANT61 for 48h. Statistical significance is indicated as p values (Student’s t-test): *p<0.05.  
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5. Conclusion and Discussion 
 
Despite improvements in patient risk stratification and definition of prognosis achieved through the 
identification of novel genetic and epigenetic alterations in pediatric AML, the majority of children 
with this disease are still treated with intensive multi-agent chemotherapy. Treatment resistance, 
occurrence of relapse, as well as short-term and long-term therapy-related side effects, highlight the 
need for new targeted therapies. Recently, the identification of the cryptic chromosomal inversion 
of chromosome 16, leading to the fusion between CBFA2T3 and GLIS2 genes, defined a novel 
subgroup of childhood AML with an adverse outcome 
115, 116, 118
. Indeed, while several other groups 
of AML and subgroups of AMKL require cooperating mutations to induce fully leukemia, 
CBFA2T3-GLIS2 imposes leukemic properties by directly regulating ERG, GATA1, in a single 
oncogenic hit. This idea is also supported by the lower genetic burden of CBFA2T3-GLIS2 
leukemic cells 
118
, and could also explain the dismal prognosis. More importantly, gene expression 
profiling of patients harboring this fusion gene demonstrated an upregulation of HH signaling 
115, 
143
. Emerging evidences are supporting the role of HH pathway deregulation in the pathogenesis 
and chemo-sensitivity of AML and myelodysplastic syndrome 
132, 144
. For this reason HH pathway 
inhibitors could be envisaged as agents able to potentiate the effect of traditional drugs and to 
restore chemo-sensitivity. GANT61 is a small molecule inhibiting DNA binding of GLI family 
proteins, and it is largely used in preclinical studies 
132, 137
. In order to investigate the possible 
benefit of GANT61 in CBFA2T3-GLIS2-positive leukemia, we approached different in-vitro 
preclinical models. We demonstrated that CBFA2T3-GLIS2-postive cells were more sensitive to 
GANT61 than the cell lines without CBFA2T3-GLIS2. Moreover, GANT61 had a marked effect on 
cell proliferation and in inducing the apoptosis only on CBFA2T3-GLIS2-positive cells, suggesting 
that the effect of the drug derived from specific inhibition of the chimeric transcriptional factor 
CBFA2T3-GLIS2. Interestingly, similar results were obtained also in primary blast cells from a 
AMKL patient harboring CBFA2T3-GLIS2fusion gene.  
To define the implication of GANT61 treatment on expression of HH signaling target genes, gene 
expression profiling and qPCR of specific genes have been performed on untreated and treated 
CBFA2T3-GLIS2-positive cells. The Expression of CRISP3, GATA3, ERG or H2FAY, known target 
genes of CBFA2T3-GLIS2 pathway, after the treatment with GANT61 was lower than in untreated 
cells, suggesting specific inhibition of GLIS2 transcription factor. Beside the inhibition of HH 
pathway, we were able to identify additional genes implied in cell proliferation, cell cycle 
regulation and DNA methylation that were significantly downregulated after treating the cells with 
GANT61. Of particular relevance, two genes involved in chromatin remodeling and DNA 
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methylation, DNMT1 and DNMT3B, were expressed at very low levels after GANT61 treatment. 
DNMT genes encode for a crucial mediator of DNA methylation that catalyzes the transfer of 
methyl groups to DNA. In a variety of solid tumors and blood cancers, aberrant hypermethylation 
of CpG-rich regions in the promoters of tumor suppressor genes (TSGs) results in their 
transcriptional silencing 
145
. DNMT1 plays a role in leukemic stem cell (LSCs) biology. Conditional 
knockout of DNMT1 blocks the development of leukemia, impairs LSCs self-renewal, reduces 
DNA methylation and TSGs re-expression without affecting normal hematopoiesis 
146
. Recently it 
was reported that high expression of DNMT3B predicts adverse outcome in older CN-AML patients 
147
. Furthermore, ChIP analysis demonstrated that CBFA2T3-GLIS2 protein directly regulated 
expression of DNMT1 and DNMT3B. This finding is particularly relevant, because overexpression 
of DNA methyltransferase genes could lead to DNA hypermethylation and could participate in the 
leukemogenesis process. 
Although the tumor-derived cell lines are the most popular model used in preclinical studies, they 
may contain additional abnormalities due to their derivation, and thus may not properly represent 
patient’s leukemic cells. Therefore in order to characterize the consequences of CBFA2T3-GLIS2 
on early stages of human hematopoiesis and to test GANT61, we developed a model of CBFA2T3-
GLIS2 expression in induced pluripotent stem cells (iPSC) derived from healthy human CD34+ 
cells. 
We demonstrated that the expression of CBFA2T3-GLIS2 in the hematopoietic cells derived from 
iPSC differentiation  reproduced  molecular features of human  pediatric AMKL such as increasing 
expression of GATA3 and ERG two known direct target of the fusion
114
. In addition, the 
cytofluorimetric analysis of megakaryocytic markers suggested that the expression CBFA2T3-
GLIS2 in hematopoietic progenitors enhanced  the aberrant differentiation of megakaryocytic cells. 
Indeed, we observed differentiation alterations, including a lower expression of CD61 on 
CBFA2T3-GLIS2 megakaryocytes compared to CTRL and a progressive accumulation of an 
abnormal CD41
low
CD42
low
 population never detected in control conditions. Moreover, clonogenic 
assays in methylcellulose indicated that CBFA2T3-GLIS2 enhances serial replating activity for 
several weeks. This result supports the idea that CBFA2T3-GLIS2 enhances proliferation of 
hematopoietic cells and it is sufficient to induce full leukemia. 
Finally the treatment of hematopoietic cells derived from iPSC differentiation expressing 
CBFA2T3-GLIS2 demonstrated that GANT61 significantly inhibited the proliferation of CBFA2T3-
GLIS2 cells compared to CTRL cells. Interestingly, GANT61 affected proliferation of CBFA2T3-
GLIS2 in  iPSC model  at concentrations extremely lower compared to that used for AML cell lines 
(2 uM and 8-15 uM respectively). This difference could be due to the complex karyotype and 
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molecular background of AML cell lines. The efficacy at lower concentration than cell lines of 
GANT61 in the human high fidelity iPSC model supports its potential application in clinical 
practice.  
Overall, these data support the idea that expression of CBFA2T3-GLIS2 in human hematopoietic 
cells enhanced self-renewal of progenitors and aberrant differentiation of megakaryocytic cells. 
Although further studies in iPSC model will be required to confirm these results, our experience 
with GANT61 could represent a preliminary background for evaluating in-vivo inhibition of 
GLIS2–mediated transcription in AML harboring CBFA2T3-GLIS2 fusion gene.  
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